Next Article in Journal
Molecular Adjuvant Ag85A Enhances Protection against Influenza A Virus in Mice Following DNA Vaccination
Next Article in Special Issue
Characterization of Clade 2.3.2.1 H5N1 Highly Pathogenic Avian Influenza Viruses Isolated from Wild Birds (Mandarin Duck and Eurasian Eagle Owl) in 2010 in Korea
Previous Article in Journal
Large Animal Models for Foamy Virus Vector Gene Therapy
Previous Article in Special Issue
Innate Immunity to H5N1 Influenza Viruses in Humans
Open AccessReview

Development of Live-Attenuated Influenza Vaccines against Outbreaks of H5N1 Influenza

by Dan Zheng 1,†, Yinglei Yi 1,† and Ze Chen 1,2,*
1
Shanghai Institute of Biological Products, 1262 YanAn Road(w), 200052, Shanghai, China
2
College of Life Sciences, Hunan Normal University, Changsha Yuelushan 410081, Hunan, China
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Viruses 2012, 4(12), 3589-3605; https://doi.org/10.3390/v4123589
Received: 2 October 2012 / Revised: 14 November 2012 / Accepted: 22 November 2012 / Published: 10 December 2012
(This article belongs to the Special Issue H5N1 Influenza Virus)
Several global outbreaks of highly pathogenic avian influenza (HPAI) H5N1 virus have increased the urgency of developing effective and safe vaccines against H5N1. Compared with H5N1 inactivated vaccines used widely, H5N1 live-attenuated influenza vaccines (LAIVs) have advantages in vaccine efficacy, dose-saving formula, long-lasting effect, ease of administration and some cross-protective immunity. Furthermore, H5N1 LAIVs induce both humoral and cellular immune responses, especially including improved IgA production at the mucosa. The current trend of H5N1 LAIVs development is toward cold-adapted, temperature-sensitive or replication-defective vaccines, and moreover, H5N1 LAIVs plus mucosal adjuvants are promising candidates. This review provides an update on the advantages and development of H5N1 live-attenuated influenza vaccines. View Full-Text
Keywords: influenza; H5N1; live-attenuated influenza vaccines; cross-protection; adjuvants influenza; H5N1; live-attenuated influenza vaccines; cross-protection; adjuvants
MDPI and ACS Style

Zheng, D.; Yi, Y.; Chen, Z. Development of Live-Attenuated Influenza Vaccines against Outbreaks of H5N1 Influenza. Viruses 2012, 4, 3589-3605.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Search more from Scilit
 
Search
Back to TopTop